BMY241129C57000
- 2.16
- 0.000.00%
Bristol-Myers Squibb Newsroom
December Starts With a Mixed Market | Live Stock
Ovarian Cancer Therapeutics Business Research Report 2024-2030, Profiles of 12 Players Including Amgen, AstraZeneca, and Bristol-Myers Squibb Company
Is Bristol-Myers Squibb Stock a Millionaire Maker?
Catalyst Watch: November Jobs, OPEC+ Meeting, Marvell, Salesforce Earnings
Wednesday Ends With Index Decline | Wall Street Today
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
Dow Falls After Record, Trump Talks Tariffs on Day One | Live Stock
Bristol Myers Squibb to Participate in Citi's 2024 Global Healthcare Conference
Bristol-Myers Squibb Hits 14-month High
Merck Phase 3 Study of Winrevair in PAH Meets Primary Endpoint
S&P 500, Dow Hit Records Right After Open | Live Stock
Bernstein Adjusts Price Target on Bristol-Myers Squibb to $62 From $56, Keeps Market Perform Rating
Optimistic Buy Rating for Bristol-Myers Squibb Driven by Promising Cobenfy Projections and Competitive Advantages
Bristol-Myers Squibb (NYSE:BMY) Increases 4.7% This Week, Taking One-year Gains to 24%
Pension Doubles Its Palantir Stake and Buys Up Intel and CVS. -- Barron's
Weekly Buzz: Nvidia Falls on Near Perfect Report, but Only For a Day
Market Climbs, Bitcoin Close to $100k | Live Stock
Replimune Climbs After Updates on Lead Drug